P
Pekka Anttila
Researcher at University of Helsinki
Publications - 39
Citations - 645
Pekka Anttila is an academic researcher from University of Helsinki. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 13, co-authored 36 publications receiving 503 citations. Previous affiliations of Pekka Anttila include Helsinki University Central Hospital.
Papers
More filters
Journal ArticleDOI
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma.
Meletios A. Dimopoulos,Antonio Palumbo,Paolo Corradini,Michele Cavo,Michel Delforge,Francesco Di Raimondo,Katja Weisel,Albert Oriol,Markus Hansson,Angelo Vacca,María Jesús Blanchard,Hartmut Goldschmidt,Chantal Doyen,Martin Kaiser,Mario Petrini,Pekka Anttila,Anna Maria Cafro,Reinier Raymakers,Jesús F. San-Miguel,Felipe de Arriba,Stefan Knop,Christoph Röllig,Enrique M. Ocio,Gareth J. Morgan,Neil Miller,Mathew Simcock,Teresa Peluso,Jennifer Herring,Lars Sternas,Mohamed H. Zaki,Philippe Moreau +30 more
TL;DR: It is confirmed that this regimen offers clinically meaningful benefit and is generally well tolerated and presented the largest trial to date evaluating pomalidomide plus low-dose dexamethasone in patients with RRMM.
Journal ArticleDOI
The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia.
TL;DR: The male gender should be regarded as a risk factor when deciding about the indication for treatment for treatment of essential thrombocythemia and smoking should be discouraged especially among women with ET.
Journal ArticleDOI
A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma.
Raija Silvennoinen,Pekka Anttila,Marjanna Säily,Tuija Lundán,J Heiskanen,Timo Siitonen,Sakari Kakko,Mervi Putkonen,Hanna Ollikainen,Venla Terävä,A. Kutila,K Launonen,A. Räsänen,Anu Sikiö,Merja Suominen,Piotr Bazia,Kristiina Kananen,Tuomas Selander,Taru Kuittinen,Kari Remes,Esa Jantunen +20 more
TL;DR: Although CY-based mobilization was more effective, G-CSF alone was successful in a great majority of patients to reach the defined collection target after three cycles of lenalidomide-based induction in multiple myeloma.
Journal ArticleDOI
Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing.
Muntasir Mamun Majumder,Raija Silvennoinen,Pekka Anttila,David Tamborero,Samuli Eldfors,Bhagwan Yadav,Riikka Karjalainen,Heikki Kuusanmäki,Juha Lievonen,Alun Parsons,Minna Suvela,Esa Jantunen,Kimmo Porkka,Caroline A. Heckman +13 more
TL;DR: The results demonstrate that ex vivo drug testing may potentially be applied to optimize treatment selection and achieve therapeutic benefit for relapsed/refractory MM.
Journal ArticleDOI
Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma
Meletios A. Dimopoulos,Sara Bringhen,Pekka Anttila,Marcelo Capra,Michele Cavo,Craig E. Cole,Cristina Gasparetto,Vania Hungria,Matthew W Jenner,Vladimir I. Vorobyev,Eduardo Yanez Ruiz,Jian Y Yin,Rao Saleem,Maeva Hellet,Sandrine Macé,Bruno Paiva,Ravi Vij +16 more
TL;DR: Adding dexamethasone to isatuximab increased response rates and survival outcomes with no detrimental effect on safety in relapsed/refractory multiple myeloma.